ABL Diagnostics S.A. (Euronext: ABLD – ISIN: FR001400AHX6) informs the market that the non-binding Letter of Intent entered into between ProPhase Labs, Inc. and Advanced Biological Laboratories S.A. ( ...

With a few minutes of searching, anyone can find videos online of chatty birds: macaws talk to their keepers, cockatoos sing to the camera, corvids mimic the jarring sounds of construction sites.

ABL Bio is seen to have surpassed 100 billion won in sales last year. It is the first time in nine years since its founding. This is analyzed to be because it transferred technology to GSK plc and ...

ABL Bio said on the 19th that the U.S. Food and Drug Administration (FDA) approved the phase 1 investigational new drug (IND) application for its bispecific Antibody-Drug Conjugate (ADC) candidate ...

SAN FRANCISCO — ABL Bio is closing in on another partnership with a global pharmaceutical company for its proprietary Grabody-B technology, a blood-brain barrier shuttle platform designed to improve ...

ABL Diagnostics Informs the Market of a Non‑Binding Letter of Intent Between ABL S.A. and ProPhase Labs (Nasdaq: PRPH) for a Proposed Reverse Merger The contemplated transaction remains subject to due ...

Energy and marine consultancy ABL has secured new five-year contracts with long-term client Woodside Energy that expands its existing workscope outside of Australia. ABL has been awarded a global ...

South Korea’s newest billionaire is Lee Sang-hoon, founder of Seoul-based ABL Bio, after it struck a $2.6 billion licensing and joint research deal with Eli Lilly for its bispecific antibody ...

ABL Bio Inc. inked a license and research agreement with Eli Lilly and Co. worth up to $2.6 billion to develop multiple therapeutics using the Grabody-B platform. Under the terms announced Nov. 12, ...

Neok Bio has exited stealth with $75 million to take a pair of bispecific antibody-drug conjugates sourced from ABL Bio into the clinic. ABL, a Korean biotech that is partnered with companies ...

Progress Software Corporation (NASDAQ:PRGS) is one of the most undervalued technology stocks to buy according to analysts. On September 29, Progress Software announced the early customer review and ...